Research

Community-Based Surveillance in Clinical Stage I Germ Cell Tumors


 

Objective: Although depression is prevalent among cancer patients, it remains underdiagnosed and undertreated. Quality of life is an important outcome in cancer patients and can be measured by questionnaires such as the Functional Assessment of Cancer Therapy-General version (FACT-G). The purpose of our study was to establish whether or not a group of items in FACT-G could be used as a screening tool for depression as well as for assessing quality of life.

Methods: A total of 62 chemotherapy patients (median age, 62 years [range, 22-81 years]; 55% women) completed Zung Self-Rating Depression Scale (ZSDS) and FACT-G questionnaires. Patients with ZSDS scores of 40 or more underwent clinical interviews for major depression. Pearson’s correlation was used to examine the relationship between the ZSDS and FACT-G scores. FACT-G score results were then analyzed to evaluate if subsets of the FACT-G can be used as a screening tool for major depression.

Results: In all, 30 of 62 patients (48%) had ZSDS scores 40 and were ruled out for major depression, and 30 of the 32 patients with ZSDS scores 40 participated clinical interviews. Of those who were interviewed, 7 patients (23%) were confirmed to have major depression. Overall, the prevalence of major depression was 7 of 60 patients (12%; 95% CI: 5%-23%). The ZSDS and FACT-G scores had strong correlation (r -0.75). The composite score of six statements in FACT-G were found to have sensitivity of 100% and specificity of 81% in predicting major depression, using a cut-off value of 12 (range, 0-24). The six statements were, I have a lack of energy; I feel sad; I feel nervous; I am able to enjoy life; I am sleeping well; and I am enjoying the things I usually do for fun.

Conclusions: The prevalence of major depression among all participants was 12%. The ZSDS score and FACT-G score had strong correlation; the subsets of FACT-G may be useful as a screening tool for depression.

*For a PDF of the full article, click on the link to the left of this introduction.

Recommended Reading

Prebiopsy Ciprofloxacin Still Best Choice to Prevent Infection
MDedge Hematology and Oncology
Prostate: Denosumab Extends Bone Metastasis-Free Survival
MDedge Hematology and Oncology
Radionuclide Therapy Alleviates Bone Pain in Prostate Cancer Patients
MDedge Hematology and Oncology
FDA Panel Backs Axitinib for Advanced Kidney Cancer
MDedge Hematology and Oncology
Panel Endorses Surveillance for Low-Risk Prostate Cancer
MDedge Hematology and Oncology
Multiparametric Magnetic Resonance Imaging Identifies Candidates for Prostate Cancer Surveillance
MDedge Hematology and Oncology
Despite Guidelines, Elderly Are Getting Cancer Tests
MDedge Hematology and Oncology
Combining MRI With Prostate Ultrasound Biopsy Bests Biopsy Alone
MDedge Hematology and Oncology
The impact of bone metastases and skeletal-related events on healthcare costs in prostate cancer patients receiving hormonal therapy
MDedge Hematology and Oncology
2011 Annual Meeting of the Radiological Society of North America: Advances in imaging aid detection of cancer
MDedge Hematology and Oncology